

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

**NOTIFICATION OF A CIVIL SUIT FILED BY A JOINT VENTURE PARTNER OF AN
INDIRECT SUBSIDIARY – RECEIPT OF WRIT OF SUMMONS**

The board of directors of Clearbridge Health Limited (the "**Company**") and together with its subsidiaries, the "**Group**") refers to the Company's announcement dated 31 May 2020 in relation to the Suit (the "**Announcement**"). Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as ascribed to them in the Announcement.

The Group wishes to announce that CBMA had, on 20 August 2020, received certain documents from the Embassy of the Republic of Indonesia in Singapore via local courier, enclosing a Writ of Summons dated 5 May 2020 in relation to the Suit filed by TMN (the "**Summons**") which was registered under the case No.227/Pdt.G/2020/PN.JKT.UTR. at the North Jakarta District Court.

The Summons relates to, among others, an allegation by TMN that a certain notarial deed has been made unlawfully as a result of the alleged unlawful conduct of the shareholders' meeting of TMJ in relation to, among others, (a) a change in the composition of the board of directors and board of commissioners of TMJ; and (b) an amendment of the articles of association of TMJ. Consequently, TMN is requesting the Court to, among others, (i) declare that the said notarial deed has been made unlawfully; (ii) award damages of IDR1.06 trillion (approximately S\$98.06 million¹) and; (iii) declare that the previous composition of the board of directors and board of commissioners of TMJ as at 18 February 2019 is legal instead. As disclosed in the Announcement, no substantiation has been provided by TMN in the Summons on how the claim for the IDR1.06 trillion has been derived. The hearing before the Court remains scheduled to be held on 11 November 2020.

CBMA and TMJ continue to be of the opinion that the aforesaid notarial deed is in accordance with the Indonesian law and there is no merit to the claim that it is unlawful. Both CBMA and TMJ have engaged Indonesian legal counsel and the Company will continue to update its shareholders if there are any material developments on this matter, to the extent that such information will not prejudice CBMA's or TMJ's position, or otherwise adversely affect any party's case, in the ongoing court proceedings. In the meantime, the operations at TMJ are unaffected by this event.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

¹ Based on an exchange rate of S\$1.00:IDR10,810 as at 21 August 2020 published by the Monetary Authority of Singapore.

BY ORDER OF THE BOARD

YEE PINH JEREMY

Executive Director and Chief Executive Officer

23 August 2020

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*